Monthly Archives: November 2017

Positions for PhD and Postdoctoral Fellows

Positions for PhD and Postdoctoral Fellows are available on a rolling basis to highly motivated candidates with the following qualifications:

• Master or diploma in biochemistry, cell biology, immunology, or a related field
• Strong academic record and knowledge in biochemistry, cell biology, and immunology
• Strong interest in inflammation, innate and adaptive immunity, and vascular biology
• Experience in basic science research and translational medicine
• Experience in murine disease models and FELASA certification is a plus
• Proficiency in English is required
• PhD in inflammation, immunity, or related field (Postdoc applicants only)
• 1+ first author publication in a top-tier journal (Postdoc applicants only)

Please submit your curriculum vitae, a statement of your research interests, and contact information of two academic references in electronic form to:

Tobias Fuchs, PhD
Principal Investigator
Laboratory of Molecular Inflammation
University Medical Center Hamburg-Eppendorf
Institute of Clinical Chemistry and Laboratory Medicine
Martinistraße 52, 20246 Hamburg, Germany

Dr. Boettcher and LMI publish article in Scientific Reports!

Dr. Boettcher and LMI publish article in Scientific Reports!

Title: “Therapeutic targeting of extracellular DNA improves the outcome of intestinal ischemic reperfusion injury in neonatal rats”


Abstract: Thrombosis and inflammation cooperate in the development of intestinal infarction. Recent studies suggest that extracellular DNA released by damaged cells or neutrophils in form of extracellular traps (NETs) contributes to organ damage in experimental models of ischemia-reperfusion injury. Here we compared the therapeutic effects of targeting fibrin or extracellular DNA in intestinal infarction after midgut volvulus in rats. Following iatrogenic midgut volvulus induction for 3 hours, we treated animals with a combination of tissue plasminogen activator (tPA) and low molecular weight heparin (LMWH) to target fibrin or with DNase1 to degrade extracellular DNA. The therapeutic effects of tPA/LMWH and DNase1 were analyzed after 7 days. We observed that both therapeutic interventions ameliorated tissue injury, apoptosis, and oxidative stress in the intestine. DNase1, but not tPA/LMWH, reduced intestinal neutrophil infiltration and histone-myeloperoxidase-complexes, a surrogate marker of NETs, in circulation. Importantly, tPA/LMWH, but not DNase1, interfered with hemostasis as evidenced by a prolonged tail bleeding time. In conclusion, our data suggest that the therapeutic targeting of fibrin and extracellular DNA improves the outcome of midgut volvulus in rats. DNase1 therapy reduces the inflammatory response including NETs without increasing the risk of bleeding. Thus, targeting of extracellular DNA may provide a safe therapy for patients with intestinal infarction in future.